Cargando…
Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data
As of today (7 April 2020), more than 81,000 people around the world have died from the coronavirus disease 19 (COVID-19) pandemic. There is no approved drug or vaccine for COVID-19, although more than 10 clinical trials have been launched to test potential drugs. In an urgent response to this pande...
Autor principal: | Alakwaa, Fadhl M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159901/ https://www.ncbi.nlm.nih.gov/pubmed/32291351 http://dx.doi.org/10.1128/mSystems.00297-20 |
Ejemplares similares
-
Efficacious Preclinical Repurposing of the Nucleoside
Analogue Didanosine against COVID-19 Polymerase and Exonuclease
por: Rabie, Amgad M.
Publicado: (2022) -
COVID-19 Hyperinflammation: What about Neutrophils?
por: Didangelos, Athanasios
Publicado: (2020) -
Great Expectations of COVID-19 Herd Immunity
por: Giurgea, Luca T., et al.
Publicado: (2022) -
The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID‐19?
por: Hondermarck, Hubert, et al.
Publicado: (2020) -
Antibody (Serology) Tests for COVID-19: a Case Study
por: West, Rachel M., et al.
Publicado: (2021)